Terazosin Capsule
Product Images NDC 70518-4545

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 70518-4545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Terazosin 2 mg capsule label showing 30 capsules per package. The label includes storage instructions to protect from light and moisture, and advises keeping medication out of children's reach. The product is repackaged by RemedyRepack Inc., Indiana, PA, with NDC 70518-4545-00 indicated. Manufacturer information lists Bionpharma Inc., Princeton, NJ.*

FDA Label Image

Image Description (Figure 01)

Figure 1 depicts two line graphs from Study 1. The left graph shows the mean change in total symptom score from baseline over three months for Terazosin versus placebo, with Terazosin showing a greater decrease. The right graph illustrates the mean increase in peak flow rate (mL/sec) from baseline over three months, with Terazosin demonstrating a larger increase compared to placebo. Both graphs include error bars and sample sizes.*

FDA Label Image

Image Description (Figure 02)

A line graph titled 'Mean Change in Total Symptom Score from Baseline' from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis shows time in months from 0 to 30; the y-axis shows mean change from baseline ranging from 0 to -7. The graph depicts a rapid decrease in symptom score during the first three months, followed by a gradual decline with data points marked by circles and asterisks indicating significance.*

FDA Label Image

Image Description (Figure 03)

A line graph titled 'Mean Change in Peak Flow Rate from Baseline' showing data from a long-term, open-label, non-placebo controlled study with 494 participants. The x-axis represents months from 0 to 30, and the y-axis shows mean change from baseline in mL/sec, ranging from 0 to 4.5. The graph illustrates an increasing trend in peak flow rate over time with several data points marked by asterisks indicating significance.*

FDA Label Image

Image Description (Structure001)

Chemical structure of Terazosin, showing its molecular formula with functional groups including methoxy, amino, piperazine ring, and a carbamate linked to a morpholine ring, along with hydrochloride and dihydrate components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.